Unique Liaison Programme between MHRA and FDA

The MHRA and US FDA have launched a new liaison programme aimed at strengthening regulatory collaboration.

Source updated: Jun 15, 2026

Primary source: Medicines and Healthcare products Regulatory Agency

PV Impact Brief

MonitoringConfidence: high

What changed

A new liaison programme was established to deepen collaboration and enhance safety monitoring between MHRA and FDA, effective from 15 June 2026.

Why it matters

This programme will increase information sharing and potentially lead to more aligned regulatory inquiries and joint oversight activities, thereby improving safety monitoring and compliance.

Action needed

MAHs should prepare for enhanced regulatory collaboration, including potential joint oversight activities and reduced market friction between the UK and US due to closer alignment in regulatory decisions.

Relevant for: Regulatory Intelligence LeadSignal Management LeadQPPV
Processes impacted: Signal ManagementCountry Compliance
Owner: Regulatory Intelligence Lead
Review cadence: Review before 2026-06-15.

Policy change details

Document type: Notice
Policy status: new
Publication date: 2026-06-15
Effective date: 2026-06-15
Policy change: The MHRA and US FDA have launched a new liaison programme aimed at strengthening regulatory collaboration. The programme focuses on innovation, clinical research standards, and enhanced safety oversight through staff exchanges and shared regulatory insights.

Key changes

Establishment of a formal staff exchange and collaborative framework for safety monitoring and clinical research oversight between the UK and US.

Affected workflows

Signal ManagementCountry Compliance

Responsible groups

Global PV StrategyRegulatory AffairsQPPV

PV impact

Increases the level of information sharing between the two regulators regarding safety signals and clinical trial oversight. MAHs may see more aligned regulatory inquiries or joint oversight activities.

View regulator source

Source document details

Exact policy details

Liaison Programme Announcement Date: 15 June 2026
Applies to: Both MHRA and FDA
Published on 15 June 2026 · p. 1 · High · Source
Focus Areas of Collaboration: Innovative medicines, medical devices, and emerging technologies such as AI
Applies to: Both MHRA and FDA
Formalises and deepens cooperation between the two agencies across key focus areas · p. 1 · High · Source

Workflow rule impacts

Country ComplianceMHRA and FDA

Reduced friction to market from the UK to the US and vice versa

Closer alignment in regulatory decisions

Our regulatory decisions will become more closely aligned, reducing friction to market · p. 1 · High · Source

Country ComplianceMHRA and FDA

Enhanced day-to-day collaboration between MHRA and FDA

Dedicated liaison officer roles

Establish dedicated, reciprocal liaison officer roles within each organisation · p. 1 · High · Source

Extracted documents

Unique liaison programme set to reinforce close collaboration between MHRA and FDAhtmlhtml · high · 1 page

Evidence and confidence

Confidence: highSource updated: Jun 15, 2026

Medicines and Healthcare products Regulatory Agency →Updated June 15, 2026

Full briefing

Practical implication

MAHs should prepare for enhanced regulatory collaboration, including potential joint oversight activities and reduced market friction between the UK and US due to closer alignment in regulatory decisions.

The MHRA and FDA have announced a liaison programme that enhances collaboration in key areas such as innovative medicines and medical devices through dedicated liaison officer roles. This initiative is aimed at improving regulatory decisions and safety oversight, and will be effective from 15 June 2026.

What changed: A new liaison programme was established to deepen collaboration and enhance safety monitoring between MHRA and FDA, effective from 15 June 2026.

Why it matters: This programme will increase information sharing and potentially lead to more aligned regulatory inquiries and joint oversight activities, thereby improving safety monitoring and compliance.

Practical implication: MAHs should prepare for enhanced regulatory collaboration, including potential joint oversight activities and reduced market friction between the UK and US due to closer alignment in regulatory decisions.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals #Notice #new #Medicines and Healthcare products Regulatory Agency #guidance #policy-change #firecrawl-policy-agent

Related updates for your role

publicFood and Drug Administration (FDA) · United States · Updated Jun 29, 2026

eMDR System Enhancements - Production Deployment

Update electronic safety reporting systems and pharmacovigilance databases to implement new rules to ensure all submissions use GENC 3-letter country codes and include the required fields as of July 20, 2026.

ICSRCountry ComplianceRegulatory Intelligence Lead

SOP Impact1 SOPs

Relevant for: Regulatory Intelligence Lead, QPPV

verifiedRegulatory action: Notice

Read impact briefarrow_forward

publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead

SOP Impact2 SOPs

Relevant for: Regulatory Intelligence Lead, PV Quality Lead

verifiedRegulatory action: Notice

Read impact briefarrow_forward

publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead

SOP Impact2 SOPs

Relevant for: Regulatory Intelligence Lead, Signal Management Lead

verifiedRegulatory action: Agenda

Read impact briefarrow_forward

publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead

SOP Impact1 SOPs

Relevant for: Regulatory Intelligence Lead, PV Quality Lead

verifiedRegulatory action: Checklist

Read impact briefarrow_forward